Scout Bio licenses new Penn technology to help develop gene therapies for pets

In order to make its gene therapies for pets easier and cheaper to produce, Scout Bio licensed Penn gene-therapy technology, specifically a type of capsid that can act as a delivery method for gene therapies. The partnership is “ideally suited to deliver an entirely new paradigm to veterinary medicine,” said Jim Wilson, MD, PhD, director of the Penn Gene Therapy Program and a co-founder of Scout Bio.

Read More in the Philadelphia Business Journal

Skip to content